Rochester, Minnesota 55905


To better understand the relationship between gut barrier function and the symptomatology and pathophysiology of irritable bowel syndrome (IBS).


Inclusion criteria - Age 18 to 70 years - No abdominal surgery (except appendectomy, cholecystectomy, hernia repair, hysterectomy, and C-section). - Written informed consent Exclusion criteria - Females who are pregnant or breastfeeding - Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability) - Use of NSAIDs or aspirin within the past week (since NSAIDs affect intestinal permeability) - Use of oral corticosteroids within the previous 6 weeks - Ingestion of artificial sweeteners such as Splenda (sucralose), Nutrasweet (aspartame), lactulose or mannitol 2 days before the study tests begins, e.g. foods to be avoided are sugarless gyms or mints and diet soda. - Ingestion of any prescription, over the counter, or herbal medications which can affect gastrointestinal transit 7 days before the study begins. - Proton pump inhibitors. - Antibiotics for the preceding 60 days before the start of the study. - (vii) Alcohol intake beyond the recommended safe limit (<21 unites per week) - Bleeding disorders or medications that increase risk of bleeding from mucosal biopsies. - Known allergy to fluorescein - Inflammatory bowel diseases, celiac disease.



Primary Contact:

Principal Investigator
Madhusudan Grover, MD
Mayo Clinic

Madhusudan Grover, MD

Backup Contact:

Margaret Breen-Lyles
Phone: 5072666332

Location Contact:

Rochester, Minnesota 55905
United States

Madhusudan Grover, MD

Site Status: Recruiting

Data Source:

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.